Clinic
Ephrata Community Hospital
Ephrata Community Hospital was paid $8.10M by Medicaid between Jan 2018 and Dec 2024, across 219 billing codes. Its largest line is 99285, emergency room visit (most serious) — 30% of everything it billed.
33Billing provider infoEPHRATA COMMUNITY HOSPITAL
EPHRATA, PA 17522
EPHRATA, PA 17522
33aNPI1083615587assigned 08/09/2005
33bProvider typeClinic/Center
28Total paid$8.10M
24GClaims228,799
24DCodes billed219
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#22 of 176
Median peer was paid$441K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 427 | $36K | |
| 2019 | 761 | $28K | |
| 2020 | 25,309 | $716K | |
| 2021 | 108,770 | $3.30M | |
| 2022 | 37,527 | $1.50M | |
| 2023 | 32,551 | $1.37M | |
| 2024incomplete | 23,454 | $1.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30% | 13,064 | 11,963 | $2.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 7,255 | 6,919 | $1.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 6,522 | 6,034 | $1.02M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.6% | 8,492 | 7,911 | $695K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 4.1% | 7,899 | 3,677 | $334K |
| G0378 | Hospital observation service, per hour | 2.7% | 228 | 219 | $217K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.0% | 1,846 | 1,789 | $160K |
| 80053 | Comprehensive metabolic panel | 1.6% | 16,296 | 15,002 | $132K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 22,016 | 19,255 | $95K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 678 | 645 | $93K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 4,844 | 4,413 | $87K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,068 | 16,321 | $79K |
207 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,283 | $75K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 800 | $71K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 600 | $65K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,472 | $61K |
| 80050 | General health panel | <1% | 1,209 | $56K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,240 | $54K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 624 | $51K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,737 | $46K |
| 80061 | Lipid panel | <1% | 3,082 | $45K |
| 81513 | <1% | 407 | $42K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,060 | $42K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,716 | $39K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,113 | $36K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,465 | $33K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 689 | $29K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,591 | $27K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 421 | $25K |
| 76830 | Ultrasound, transvaginal | <1% | 570 | $24K |
| 84702 | <1% | 2,292 | $23K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 617 | $23K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 89 | $21K |
| 59025 | Fetal non-stress test | <1% | 97 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,469 | $20K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 475 | $20K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 153 | $20K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 800 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 256 | $19K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 319 | $17K |
| 96376 | <1% | 489 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,346 | $17K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 351 | $17K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 383 | $17K |
| 84484 | <1% | 2,148 | $15K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 571 | $15K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,313 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 634 | $14K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 233 | $14K |
| 71250 | <1% | 168 | $13K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 437 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 608 | $12K |
| T1001 | Nursing assessment / evaluation | <1% | 60 | $12K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 558 | $12K |
| 81001 | <1% | 6,802 | $12K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 56 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,436 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,717 | $11K |
| 95886 | <1% | 237 | $11K | |
| 87481 | <1% | 172 | $11K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 362 | $10K |
| 93971 | <1% | 175 | $10K | |
| 83880 | <1% | 463 | $10K | |
| 84466 | <1% | 642 | $10K | |
| 83690 | <1% | 3,307 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 200 | $9K |
| 76642 | <1% | 217 | $9K | |
| 86803 | <1% | 383 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 184 | $8K |
| 85027 | <1% | 1,180 | $8K | |
| 72110 | <1% | 377 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,027 | $7K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 146 | $7K |
| 83735 | <1% | 1,542 | $7K | |
| 95800 | <1% | 85 | $7K | |
| 73564 | <1% | 377 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,476 | $7K |
| 82607 | <1% | 616 | $7K | |
| 86618 | <1% | 262 | $6K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 179 | $6K |
| 82728 | <1% | 589 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 263 | $6K |
| 84439 | <1% | 691 | $6K | |
| 87040 | <1% | 502 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 124 | $6K |
| 76801 | <1% | 147 | $5K | |
| 83540 | <1% | 680 | $5K | |
| 76536 | <1% | 92 | $5K | |
| 85610 | <1% | 1,783 | $5K | |
| 84703 | <1% | 695 | $5K | |
| 82570 | <1% | 643 | $5K | |
| 76770 | <1% | 131 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 71 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 275 | $4K |
| 87077 | <1% | 601 | $4K | |
| 72050 | <1% | 161 | $4K | |
| 86038 | <1% | 256 | $4K | |
| 83605 | <1% | 866 | $4K | |
| 83655 | <1% | 321 | $4K | |
| 73610 | <1% | 229 | $4K | |
| 82043 | <1% | 433 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $3K |
| 87186 | <1% | 456 | $3K | |
| 73030 | <1% | 240 | $3K | |
| 82784 | <1% | 133 | $3K | |
| 73630 | <1% | 286 | $3K | |
| 87653 | <1% | 70 | $3K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 701 | $3K |
| 82075 | <1% | 288 | $3K | |
| 85730 | <1% | 683 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 260 | $3K |
| 83013 | <1% | 39 | $3K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 154 | $3K |
| 87340 | <1% | 178 | $3K | |
| 87799 | <1% | 31 | $3K | |
| 85379 | <1% | 390 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 59 | $2K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 304 | $2K |
| 93970 | <1% | 27 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 43 | $2K |
| 84146 | <1% | 89 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 55 | $2K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $2K |
| 84403 | <1% | 72 | $2K | |
| 82565 | <1% | 571 | $2K | |
| 85652 | <1% | 678 | $2K | |
| 74022 | <1% | 107 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 45 | $2K |
| 86592 | <1% | 413 | $2K | |
| 84100 | <1% | 322 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 31 | $2K |
| 73130 | <1% | 179 | $2K | |
| 90715 | <1% | 92 | $2K | |
| 86140 | <1% | 603 | $2K | |
| 72070 | <1% | 89 | $2K | |
| 73110 | <1% | 136 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 25 | $1K |
| 86850 | <1% | 218 | $1K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 12 | $1K |
| 86003 | <1% | 12 | $1K | |
| 80076 | <1% | 149 | $1K | |
| 84153 | <1% | 56 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,298 | $1K |
| 86480 | <1% | 16 | $1K | |
| 94760 | <1% | 23 | $1K | |
| 93017 | <1% | 37 | $1K | |
| 83001 | <1% | 63 | $1K | |
| 82248 | <1% | 238 | $1K | |
| 84550 | <1% | 181 | $1K | |
| 73502 | <1% | 65 | $1K | |
| 82947 | <1% | 514 | $1K | |
| 83516 | <1% | 32 | $963.10 | |
| 82746 | <1% | 93 | $934.72 | |
| 87512 | <1% | 32 | $904.04 | |
| 86900 | <1% | 280 | $845.36 | |
| 86901 | <1% | 280 | $845.27 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 38 | $805.60 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,365 | $770.51 |
| 84156 | <1% | 180 | $733.29 | |
| 86431 | <1% | 94 | $709.74 | |
| 86706 | <1% | 43 | $603.12 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 781 | $574.76 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,983 | $549.80 |
| 97165 | <1% | 14 | $540.12 | |
| 80164 | <1% | 29 | $539.98 | |
| 83970 | <1% | 12 | $531.28 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,322 | $530.29 |
| 93296 | <1% | 41 | $525.99 | |
| 82950 | <1% | 70 | $509.96 | |
| 87493 | <1% | 13 | $495.95 | |
| 82550 | <1% | 88 | $478.25 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,733 | $428.53 |
| 84402 | <1% | 13 | $403.65 | |
| 94729 | <1% | 12 | $365.98 | |
| 81003 | <1% | 115 | $361.51 | |
| 83615 | <1% | 67 | $355.00 | |
| 87427 | <1% | 27 | $333.56 | |
| A9270 | Non-covered item or service | <1% | 38 | $323.75 |
| 87081 | <1% | 58 | $319.02 | |
| 77062 | <1% | 12 | $302.55 | |
| 87205 | <1% | 67 | $300.13 | |
| 84481 | <1% | 13 | $296.12 | |
| 87209 | <1% | 13 | $261.15 | |
| 94727 | <1% | 12 | $242.45 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 335 | $235.26 |
| 72040 | <1% | 12 | $224.93 | |
| 87070 | <1% | 39 | $223.75 | |
| 72100 | <1% | 12 | $220.78 | |
| 73140 | <1% | 24 | $201.30 | |
| 90686 | <1% | 13 | $189.80 | |
| 87045 | <1% | 27 | $188.98 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,894 | $185.81 |
| 74018 | <1% | 16 | $180.47 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $175.32 |
| J2704 | Injection, propofol, 10 mg | <1% | 390 | $148.06 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $148.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 518 | $146.14 |
| 82803 | <1% | 28 | $141.96 | |
| 80178 | <1% | 17 | $128.00 | |
| 94060 | <1% | 12 | $125.97 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 230 | $120.30 |
| 87046 | <1% | 27 | $117.45 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 721 | $113.16 |
| 84425 | <1% | 13 | $106.75 | |
| 87177 | <1% | 13 | $97.54 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 118 | $61.22 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 349 | $31.73 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 25 | $30.18 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 396 | $25.75 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 53 | $15.33 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 232 | $3.96 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 105 | $0.01 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 154 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 157 | $0.00 |
| J3490 | Unclassified drugs | 0% | 184 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 19 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 178 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 396 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHAMBERS, ORIE (INTERIM PRESIDENT & VP PATIENT CARE)
| Provider | Location | Paid |
|---|---|---|
| Ephrata Community Hospital | Ephrata, PA | $1.33M |
| Ephrata Community Hospital | Ephrata, PA | $107K |
| Ephrata Community Hospital-Spu | Ephrata, PA | $100K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.